Get started
666

ENIMMUNE CORPORATI

No trades
See on Supercharts
Overview
Financials Discussions Technicals Seasonals

6564 chart


Full chart

Key stats


Market capitalization
‪2.23 B‬TWD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−223.74 M‬TWD
Revenue (FY)
‪43.49 M‬TWD
Shares float
—
Beta (1Y)
0.26

About ENIMMUNE CORPORATI


Sector
Health Technology
Industry
Biotechnology
CEO
Che Wei Chang
Website
enimmune.com.tw
Headquarters
Taipei
Founded
2014
ISIN
TW0006564008
FIGI
BBG00M0C0FW5
Enimmune Corp. engages in the research, development of new drugs. Its products include EV71, Japanese encephalitis virus, EV71+CA16 bivalent, tetanus toxoid adsorbed, influenza, AH1N1, and pneumococcal vaccines. The company operates pharmaceutical outlets. Enimmune was founded on January 10, 2014 and is headquartered in Taipei, Taiwan.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 6564 is 30.90 TWD — it has decreased by −0.16% in the past 24 hours. Watch ENIMMUNE CORPORATI stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange ENIMMUNE CORPORATI stocks are traded under the ticker 6564.
6564 stock has fallen by −1.75% compared to the previous week, the month change is a −8.71% fall, over the last year ENIMMUNE CORPORATI has showed a −15.49% decrease.
6564 reached its all-time high on Jul 6, 2020 with the price of 124.85 TWD, and its all-time low was 14.00 TWD and was reached on Mar 19, 2020. View more price dynamics on 6564 chart.
See other stocks reaching their highest and lowest prices.
6564 stock is 2.48% volatile and has beta coefficient of 0.26. Track ENIMMUNE CORPORATI stock price on the chart and check out the list of the most volatile stocks — is ENIMMUNE CORPORATI there?
Today ENIMMUNE CORPORATI has the market capitalization of ‪2.23 B‬, it has decreased by −4.18% over the last week.
Yes, you can track ENIMMUNE CORPORATI financials in yearly and quarterly reports right on TradingView.
6564 net income for the last quarter is ‪−39.64 M‬ TWD, while the quarter before that showed ‪−45.95 M‬ TWD of net income which accounts for 13.73% change. Track more ENIMMUNE CORPORATI financial stats to get the full picture.
No, 6564 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 6564 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ENIMMUNE CORPORATI stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ENIMMUNE CORPORATI technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ENIMMUNE CORPORATI stock shows the strong sell signal. See more of ENIMMUNE CORPORATI technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.